Orally Delivered Stimulus‐Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease
Small · 2024
DOI: 10.1002/smll.202402502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Andreia S Barros und 9 weiteren Autor:innen. Beteiligte Einrichtung: i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, 4200-135, Portugal. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Peptides, Nanomedicine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Ferring Pharmaceuticals, Fundação para a Ciência e Tecnologia, Marie Skłodowska-Curie HORIZON-WIDERA-2022-TALENTS-04-01, PPBI - Portuguese Platform of Bioimaging.
Abstract (Originalsprache)
Inflammatory Bowel Disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract (GIT). Glucagon‐like peptide‐2 (GLP‐2) analogs possess high potential in the treatment of IBD by enhancing intestinal repair and attenuating inflammation. Due to the enzymatic degradation and poor intestinal absorption, GLP‐2 analogs are administered parenterally, which leads to poor patient compliance. This work aims to develop IBD‐targeted nanoparticles (NPs) for the oral delivery of the GLP‐2 analog, Teduglutide (TED). Leveraging the overproduction of Reactive Oxygen Species (ROS) in the IBD environment, ROS‐sensitive NPs are developed to target the intestinal epithelium, bypassing the mucus barrier. PEGylation of NPs facilitates mucus transposition, but subsequent PEG removal is crucial for cellular internalization. This de‐PEGylation is possible by including a ROS‐sensitive thioketal linker within the system. ROS‐sensitive NPs are established, with the ability to fully de‐PEGylate via ROS‐mediated cleavage. Encapsulation of TED into NPs resulted in the absence of absorption in 3D in vitro models, potentially promoting a localized action, and avoiding adverse effects due to systemic absorption. Upon oral administration to colitis‐induced mice, ROS‐sensitive NPs are located in the colon, displaying healing capacity and reducing inflammation. Cleavable PEGylated NPs demonstrate effective potential in managing IBD symptoms and modulating the disease's progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, 4200-135, Portugal.
- ICBAS- Instituto Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, 4050-313, Portugal.
- FMUP- Faculty of Medicine, University of Porto, Porto, 4200-319, Portugal.
- IUCS-CESPU-Instituto Universitário de Ciências das Saúde, Porto, 4585-116, Portugal.
- Ferring Pharmaceuticals, 1162-Saint-Prex, SA Chemin de la Vergognausaz 50, Switzerland.
ORCID-Profile: Bruno Sarmento
Förderung
- Ferring Pharmaceuticals, Fundação para a Ciência e Tecnologia
- Marie Skłodowska-Curie HORIZON-WIDERA-2022-TALENTS-04-01
- PPBI - Portuguese Platform of Bioimaging
Zitieren
APA
Barros, A. S., Pinto, S., Viegas, J., Martins, C., Almeida, H., Alves, I., Pinho, S., Nunes, R., Harris, A., & Sarmento, B. (2024). Orally Delivered Stimulus‐Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. Small. https://doi.org/10.1002/smll.202402502
Vancouver
Barros AS, Pinto S, Viegas J, Martins C, Almeida H, Alves I, et al. Orally Delivered Stimulus‐Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. Small. 2024. doi:10.1002/smll.202402502
BibTeX
@article{Barros2024,
author = {Barros, Andreia S and Pinto, Soraia and Viegas, Juliana and Martins, Claúdia and Almeida, Helena and Alves, Inês and Pinho, Salomé and Nunes, Rute and Harris, Alan and Sarmento, Bruno},
title = {Orally Delivered Stimulus‐Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202402502}
}
EUVIMED